Jim Heusden - Karolinska Development Insider

Karolinska Development AB -- Sweden Stock  

SEK 6.05  0.1  1.63%


Dr. Jim Van Heusden, Ph.D. has served as Chief Executive Officer of Karolinska Development AB since March 3, 2015. Jim Van Heusden has over 20 years of experience within VC, research and development within the pharmaceutical industry, including as Founder and Managing Director at bioskills and as Partner at the European investment company Gimv . During his appointment at Gimv he also served as a Board member in several biotech companies including Multiplicom NV, Ablynx NV, ActoGeniX NV, Pronota NV and Prosensa. During 19932001, Jim Van Heusden worked as Senior Scientist at Janssen Pharmaceuticals . He has a Ph.D. in molecular and cellular biology from the University of Maastricht.
Age: 44  CEO Since 2015  Ph.D    
46 8 52 48 60 70  http://www.karolinskadevelopment.com

Management Efficiency

The company has return on total asset (ROA) of (4.21) % which means that it has lost $4.21 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (156.17) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 357.55 M in total debt with debt to equity ratio (D/E) of 868.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Karolinska Development AB has Current Ratio of 24.99 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

Karolinska Development AB is a VC firm specializing in investments in growth capital, seed stage, and early stage companies. Karolinska Development AB (KDEV) is traded on Stockholm Stock Exchange in Sweden. It is located in Solna, and employs 13 people.

Did you try this?

Run CEO Directory Now

CEO Directory

Screen CEOs from public companies around the world
Hide  View All  NextLaunch CEO Directory
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Karolinska Development AB to your portfolio

Top Management

Karolinska Development AB Leadership Team
Hans Wigzell, Chairman, Ph.D
Elisabet Gimbringer, Executive
Carl Sundberg, Director
Magnus Persson, Director, Ph.D
Jim Heusden, CEO, Ph.D
Maria Ferm, Executive
HansOlov Olsson, Director, Ph.D
Viktor Drvota, Executive, Ph.D
Eva Montgomerie, Executive
Michael Owens, Executive
Yan Cheng, President
Ulf Richenberg, Executive
Niclas Adler, Director
Tse Ping, Director, Ph.D
Christian Tange, CFO, MBA
Daniel Bolanowski, Executive
Terje Kalland, Executive, Ph.D
Vladimir Artamonov, Director, MBA
Felicia Rittemar, Executive
AnnSofie Sternas, President
Anders Harfstrand, Director, Ph.D
Bo Hansen, Chairman, Ph.D
Viktor MD, Executive
Khalid Islam, Director, Ph.D
Gunilla Ekstrom, President, Ph.D
Henrijette Richter, Director

Stock Performance

Karolinska Development Performance Indicators